Table 1.
Patients' characteristics
| High–risk | Very–high–risk | |
|---|---|---|
| n | 96 | 82 |
| Age | 72 (57–87) | 72 (54–87) |
| Clinical T stage | ||
| T1c | 38 | 4 |
| T2a | 3 | 1 |
| T2b | 26 | 3 |
| T2c | 8 | 1 |
| T3a | 20 | 43 |
| T3b | 1 | 28 |
| T4 | 0 | 2 |
| Gleason score | ||
| 10 | 2 | 1 |
| 9 | 8 | 21 |
| 8 | 21 | 18 |
| 4 + 3 | 20 | 23 |
| 3 + 4 | 26 | 15 |
| 6 | 14 | 4 |
| 5 | 5 | 0 |
| Initial PSA (ng/ml) | 19.9 (3.3–159) | 40.5 (2.7–337.6) |
| Prostate volume (ml) | 20.7 (9.5–63.5) | 18.8 (6.9–60.8) |
| Neoadjuvant ADT (months) | 12 (8–28) | 13 (7–74) |
Values are number or median (range)
PSA, prostate specific antigen; LNI, lymph-node involvement
ADT; androgen deprivation therapy